Glenmark Pharmaceuticals Inc., USA launches Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules. Glenmark's Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules is bioequivalent and therapeutically equivalent to the reference listed drug, Vitamin K1 Injectable Emulsion USP, 10 mg/mL of Hospira, Inc., ANDA 087955.

According to IQVIATM sales data for the 12-month period ending November 2024, the Vitamin K1 Injectable Emulsion USP, 10 mg/mL market achieved annual sales of approximately $19.7 million*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, "We are excited to announce the launch of Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules, growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring to market quality and affordable alternatives for patients."

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 1499.80 as compared to the previous close of Rs. 1504.25. The total number of shares traded during the day was 8674 in over 1343 trades.

The stock hit an intraday high of Rs. 1537.90 and intraday low of 1495.75. The net turnover during the day was Rs. 13126977.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 USALaunch PhytonadioneInjectableEmulsion